This episode of the Market Pathways Podcast tackles the biggest problem facing device companies today: reimbursement. Ask medtech executives and investors the biggest change in the challenges currently confronting product companies compared with a decade ago and the overwhelming consensus response is that reimbursement has replaced regulatory as the biggest obstacle to successful commercialization. Dealing with the multiple elements of reimbursement - coding, coverage and payment - which involve a variety of public and private organizations, makes this a complex pathway for small and large companies alike, and that doesn’t even begin to address international coverage.
Our recent San Francisco Innovation Summit, held in November 2021, featured a reimbursement panel moderated by Stephen Levin, Market Pathways’ Editor-in-Chief, that, rather than talking in hypothetical terms, highlighted perspectives from two companies with innovative cardiovascular technologies that have successfully navigated the reimbursement process, and an experienced consultant who has worked with many device companies to achieve payment for their products.
The panelists were Christopher Brooks, Director of Healthcare Economics for Impulse Dynamics NV (implantable device for heart failure), Heather A. Brown, SVP of Market Access and Reimbursement for Heartflow Inc. (non-invasive coronary artery disease diagnosis), and Adi Renbaum, president of ANR Consulting. An excerpt from this discussion also appears in the January 2022 issue of Market Pathways. We hope you enjoy the podcast.
View the latest issue of Market Pathways: https://bit.ly/2UEqmO9
View more podcast episodes: https://bit.ly/3AvBFrm
About Market Pathways
Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com
